View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 4, 2011

GlaxoSmithKline Joins Fight Against Doping in Sport

UK-based pharmaceutical major GlaxoSmithKline has signed a long-term agreement with the World Anti-Doping Agency to help detect emerging performance-enhance drugs in sport. Under the agreement, the agency will have access to products that could be used as performance-enhancing drugs

By cms admin

UK-based pharmaceutical major GlaxoSmithKline has signed a long-term agreement with the World Anti-Doping Agency to help detect emerging performance-enhance drugs in sport.

Under the agreement, the agency will have access to products that could be used as performance-enhancing drugs in the early stages of their development, allowing it to pre-emptively develop tests to detect them.

Scientists will analyse new drugs for stimulatory or performance enhancing effects and flag them, with data being delivered to the World Anti-Doping Agency.

Similar partnerships have proven beneficial in the past, such as when Amgen helped drug testers develop a detection method for Aranesp, leading to three athletes at the 2002 Winter Olympic Games being caught.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology